Division of Hematology and Oncology Archive — Page 5 of 15

Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan
March 16, 2023

Eng stresses need for clinical trial support at cancer forum

Vanderbilt’s Cathy Eng, MD, stressed the need for more patient participation and better funding for clinical trials to improve colorectal cancer treatment and outcomes during the White House Cancer Moonshot Colorectal Cancer Forum.

By Tom Wilemon
March 2, 2023

Eng invited to White House Cancer Moonshot forum

Vanderbilt’s Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.

By Tom Wilemon
February 16, 2023

Targeted therapy for neuroendocrine tumors

Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.

By Kelsey Pinckard
February 6, 2023

Berlin named director of Division of Hematology and Oncology

Jordan Berlin, MD, has been named director of Vanderbilt’s Division of Hematology and Oncology.

By Tom Wilemon
December 8, 2022

Lovly receives Asclepios Award from GO2 for Lung Cancer

Vanderbilt’s Christine Lovly, MD, PhD, has received the 2022 Asclepios Award, which recognizes lung cancer research pioneers.

By Tom Wilemon